Skip to content
The Policy VaultThe Policy Vault

Kevzara (sarilumab subcutaneous injection – Regeneron/SanofiAventis)Cigna

Polymyalgia rheumatica

Initial criteria

  • Patient age > 18 years
  • Patient has tried one systemic corticosteroid
  • Medication is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

  • Patient has been established on therapy for at least 6 months
  • Patient experienced a beneficial clinical response from baseline assessed by at least one objective measure OR improvement in at least one symptom

Approval duration

initial 6 months; reauth 1 year